KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other financing activities (2016 - 2024)

Emergent BioSolutions has reported Other financing activities over the past 10 years, most recently at $8.7 million for Q3 2024.

  • For Q3 2024, Other financing activities changed N/A year-over-year to $8.7 million; the TTM value through Dec 2025 reached $8.7 million, changed 0.0%, while the annual FY2024 figure was $14.6 million, N/A changed from the prior year.
  • Other financing activities for Q3 2024 was $8.7 million at Emergent BioSolutions, down from $13.4 million in the prior quarter.
  • Over five years, Other financing activities peaked at $8.7 million in Q3 2024 and troughed at $8.7 million in Q3 2024.